On August 11, Hims & Hers Health Inc. fell 6.37% in pre-market trading, trading at $29.57/share. The decline was triggered by the company's Q2 earnings report revealing a sharp swing from profit to loss despite strong top-line growth.

Hims & Hers Health Inc. reported Q2 revenue of $753 million, up 38% year-over-year, with subscribers growing to approximately 2.89 million. However, the company posted an EPS loss of $0.37, dramatically worse than the consensus estimate of a $0.03-$0.05 loss and a stark reversal from EPS of $0.17 in the year-ago period. Gross margin contracted sharply from 76% to 64%, with management attributing the deterioration to international expansion and branded GLP-1 weight loss drug sales generating restructuring costs. The CFO indicated gross margins will remain below historical levels long-term. The company raised full-year revenue guidance to $3.1-$3.3 billion and expressed confidence in its 2030 target of at least $6.5 billion in revenue, but the magnitude of the earnings miss overwhelmed the positive revenue outlook.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)